RxDoctor Payments Data

Anna Fehrenbacher, MD

Family Medicine · Evansville, INNPI 1407205958

Payments from drug & device makers

$3,784in general payments, 2019–2025

Across 249 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$998
  • GSK$307
  • Pfizer$235
  • AstraZeneca$230
  • Novo Nordisk$218
  • Amgen$205
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,784 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$143,162
Medicare patients
272
Services billed
1,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$80,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$48,530
EliquisApixaban36$43,742
FarxigaDapagliflozin Propanediol35$29,397
MounjaroTirzepatide17$25,200
XareltoRivaroxaban24$25,016
Spiriva RespimatTiotropium Bromide18$17,747
JanuviaSitagliptin Phosphate16$16,368
QuliptaAtogepant11$11,942
Victoza 3-PakLiraglutide11$8,910
Breo ElliptaFluticasone/Vilanterol14$7,642
SynthroidLevothyroxine Sodium47$3,951
BijuvaEstradiol/Progesterone13$3,214
Albuterol Sulfate HfaAlbuterol Sulfate123$2,974
Atorvastatin Calcium505$2,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$218$80,51159 claims
GSKTrelegy Ellipta, Breo Ellipta$307$56,17271 claims
PfizerEliquis$235$43,74236 claims
AstraZenecaFarxiga$230$29,39735 claims
Lilly USA, LLCMounjaro$65$25,20017 claims
Johnson & JohnsonXarelto$24$25,01624 claims
Boehringer IngelheimSpiriva Respimat$58$17,74718 claims
MerckJanuvia$82$16,36816 claims
AbbVieQulipta, Synthroid$998$15,89358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →